Retraction: Sensitizing Estrogen Receptor–negative Breast Cancer Cells to Tamoxifen with OSU-03012, a Novel Celecoxib-derived Phosphoinositide-dependent Protein Kinase-1/Akt Signaling Inhibitor

Retraction: Sensitizing Estrogen Receptor–negative Breast Cancer Cells to Tamoxifen with OSU-03012, a Novel Celecoxib-derived Phosphoinositide-dependent Protein Kinase-1/Akt Signaling Inhibitor

This article (1) has been retracted at the request of the editors. Following institutional review by the Ohio State University it was determined that Fig. 4A and B were intentionally falsified by Dr. Ching-Shih Chen. The authors regret any inconveniences or challenges resulting from the publication and subsequent retraction of this article. A copy of this Retraction Notice was sent to the last known email addresses for the authors. Three authors (S.K. Kulp, R.W. Brueggemeier, and C.L. Shapiro) agreed to the retraction; the four remaining authors (S-C. Weng, Y. Kashida, D. Wang, and C-S. Chen) could not be located.



Also in Industry News

1.5 Million Israelis Using Voluntary Coronavirus Monitoring App
1.5 Million Israelis Using Voluntary Coronavirus Monitoring App

0 Comments

1.5 Million Israelis Using Voluntary Coronavirus Monitoring App

Read More

ATS releases new guidance to help clinicians manage COVID-19 patients
ATS releases new guidance to help clinicians manage COVID-19 patients

0 Comments

ATS releases new guidance to help clinicians manage COVID-19 patients

Read More

Cancer patients face treatment delays and uncertainty as coronavirus cripples hospitals
Cancer patients face treatment delays and uncertainty as coronavirus cripples hospitals

0 Comments

Cancer patients face treatment delays and uncertainty as coronavirus cripples hospitals

Read More